Liver cancer drug trial halted early – but holds promise for High-Risk patients
NCT ID NCT06851104
First seen Feb 19, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study looked at whether the drug cadonilimab could help keep liver cancer from returning after surgery in patients at high risk of recurrence. It involved 45 adults who had their liver cancer completely removed. The trial was stopped early, but the goal was to see if the drug could safely extend the time without cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.